INDEX

“10 plus 10” tender offers
consent solicitations, 87–8
18-day and 20-day fixed spread pricing
Regulation 14E under Securities Exchange Act, 80–1
“20 Business Days” Rule
Regulation 14E under Securities Exchange Act, 66–9
ability to finance offer
disclosure guidelines, 100–1
“accredited” investors
exchange offers, 181–2
amendment of indenture terms see
consent solicitations
basic or fundamental economic terms, 256–7
announcements see public announcements
anti-fraud measures
exchange offers, 193–4
repurchases of debt securities, 18–1
Section 14(e) of Securities Exchange Act see Section 14(e) of Securities Exchange Act
“any court” definition, 175–6
artificial transactions overview, 128–9
available information see information
banks
as “accredited” investors, 181–2
consent solicitations, 254, 260,
263–4, 271, 272, 293–4, 295
exchange offers, 156, 167–8, 169–70,
173–4
interest rates, 119–20
private placements, 180, 182–3
as solicitation agents, 28
tender offers, 102–3, 220–1,
223–4
basic economic terms
amendment of indenture terms,
256–7
“bond buybacks” inside information, 130
brokers/dealers
appointment of, 26–7, 40–1
communications between, 52–3
information dissemination, 102–3,
167, 169–70, 272
material misrepresentations and
omissions by, 238, 241
obligations as to communications,
271, 272
as potential defendants, 247–8
prospectus delivery, 149
protection for, 94
trade among, 48–9, 77
use of, 2, 14–15, 17–18, 51–2, 68–9,
94, 195–6, 210–11, 229
cash payments exceeding market value, 290,
295
cash purchases debt securities, 7–8
cash tender offers liability management generally,
22–5
as liability management option, 2
causation materiality distinguished, 228–9
INDEX

cause of action
  debt repurchases, 203
debt tender offers see Section 14(e)
of Securities Exchange Act
central banks see banks
commission
  Section 3(a)(9) exchange offers, 166–7
commodities
  market distortion, 138–9
communications see information
compensation
  exchange offers, 156
compliance
  consent solicitations, 267, 272,
    279–80, 281–2
debt repurchases, 210
EU treaty freedoms, 110
exit consents, 291
fixed-spread pricing, 74–5
indentures, 28
mutual recognition of national laws, 109
offshore offers, 187, 188–90, 192
options, 13
redemptions, 11
registered exchange offers, 145–6
regulatory framework overviewed,
  31–2
SEC Releases see Securities and
  Exchange Commission (SEC),
  Releases
waterfall structures, 89–90
  see also filing
conditions to offer
  disclosure guidelines, 101
consent solicitations
  “10 plus 10” tender offers, 87–8
  amendment of indenture terms
    basic or fundamental economic
    terms, 256–7
  consents of holders in all other
    circumstances, 263–4
  generally, 254–5
  unanimous consents for material
    terms (Section 316(b) of Trust
    Indenture Act), 257–63
  without consent of holders, 255–6
banks as agents, 28
definition of “solicitation,” 43,
  266–7
disclosure items, 269–70
exit consents
  English law, 293–5
  Federal securities laws, 291
generally, 285–7
  legal framework generally, 31
  legality, 287
payments for, 292
  Trust Indenture Act, 292–3
introduction to, 252–4
liability management generally,
  28–9
“New Security” doctrine under
  Securities Act
case law, 274–7
“fundamental change” defined,
  284
generally, 272–4
  SEC position, 277–84
Regulation 14A of Securities
  Exchange Act
“consent solicitations” defined,
  265–7
content of statements, 267–71
debt securities listed on US
  exchanges, 271–2
generally, 264–5
“proxy” defined, 266
“solicitation” defined, 266–7
“solicitation,” Wellman test
  definition, 43
solicitation agents, banks as, 30
  stand-alone consents, 27–29
waivers, 27
Wellman test, 43
contract-based manipulations
  overview, 131
contractual limitations
  repurchases of debt securities,
    21–2
corporate actions
  “bond buybacks” preceding other,
corporate bonds
exit consents, 292
postponed payments, 263–4
corporate cash buyers
exit consents, 288–9
corporate communications see information; prospectus; public announcements
corporate constitutional document amendment, 157
corporate control
acquisition of, 23, 30, 31, 38, 43, 237–8
see also corporate takeovers
regulatory frameworks, 115
strengthening of regulation, 113
transfer of, 6
Wellman test see Wellman test
corporate debt holders contractual relationship with corporation, 289–90
corporate defendants “manipulative practice,” 244
corporate groups multinational transactions, 142–3
corporate information see information
corporate insiders prohibited conduct, 241
corporate internal transactions identity of issuer, 160
corporate issuers commercial objectives, 4
debt repurchases see debt repurchases
debt securities issued by, 5
equity securities, 5
liability management options, 2
corporate policy information as to, 118
corporate restructuring commercial objectives, 140
consent solicitations see consent solicitations
exchange offers see exchange offers exemptions from registration, 144
“New Security” doctrine, 272
as objective, 3–4

prevention of market distortion, 112–13
related transactions, 141–2
corporate seat change of, 161
corporate statements reliance on, 245–6
corporate stock indentures, 257
materiality see materiality
corporate takeovers by cash tender offer, 30–1, 38
Directive see European Union
harmonization of EU regulation, 105–6, 115
regulatory discouragement of, 243
strengthening of regulation, 113
takeover bid as inside information, 121, 123–4
takeover bid defined, 113
corporate tender offerors disclosure of directors’ identities, 100
corporations transfer of control, 23
courts “any court” defined, 176
approval of terms and conditions, 175–6
fairness hearing, 176
dealers see brokers/dealers
debt exchange offers see exchange offers
debt repurchases cause of action, 203
corporate law issues as to, 212
disclosure requirements
Regulation 10B-5 under Securities Exchange Act, 200–5
Regulation FD under Securities Exchange Act, 209–10
Regulation M under Securities Exchange Act, 210
special issues as to, 207–9
introduction to, 195
as liability management option, 2
public announcements “in connection with” tender offer, 18–20
structuring of transactions, 210–11
tax issues as to, 212–13
tender offer rules applied to, 196–9
transaction structures, 14, 195–6
trust deeds, 211
debt securities
cash purchases, 7–8
equity securities distinguished, 5–6
exchange offers see exchange offers
liability management generally see liability management
redemptions, 8–13
Regulation 14E of Securities Exchange Act, 81–2
repurchases
anti-fraud measures, 18–1
avoidance of US Tender Offer Rules, 15–18
contractual limitations, 21–2
disclosure issues, 18–21
liability management generally, 13–14
tax issues, 22
transaction types, 14–15
secondary market transactions, 6–7
transaction types, 6–8
debt tender offers
anti-fraud protection see Section 14(e) of Securities Exchange Act
equity tender offers contrasted, 33–5, 62–3
EU regulation see European Union
UK regulation see United Kingdom
US rules see Regulation 14E under Securities Exchange Act
defective acts or practices
Section 14(e) of Securities Exchange Act, 242–4
definitions see words and phrases
derivatives
inside information, 118, 119–20, 125–6
manipulation of transactions, 135–6, 137
price-sensitive information, 121–3, 206–7
shareholder actions, 212
Directives see European Union
disclosure
consent solicitations, 269–70
debt repurchases see debt repurchases
defined, 20
improper disclosure, 134
Regulation 14E under Securities Exchange Act
disclosure guidelines, 98–101
dissemination guidelines, 101–3
overview, 97–8
Section 4(2) exchange offers, 182
dissemination
“20 Business Days” rule, 67
definition, 138
Regulation 14E under Securities Exchange Act, 101–3
distortion
definition, 138–9
Dutch auctions
cash tender offers, 24–5
Regulation 14E of Securities Exchange Act, 71–2
economic rights
definition, 5
economic terms
amendment of indenture terms, 256–7
Embassy Suites No-Action Letter
Extension of the Offering Period Rule, 73–4
employee stock ownership plans
options, 155–6
enforcement see Securities and Exchange Commission (SEC)
English law see United Kingdom
equal treatment
UK regulation, 139
equity securities

debt securities distinguished, 5–6
equity tender offers
debt tender offers contrasted, 33–5, 62–3
definition, 23
rules overviewed, 34–5
European Union
capital markets directives, 13
consent solicitations, 27–28
debt securities, 205–7
defenses and exemptions, 123–4
exchange offers, 190–1
information of precise nature, 120–1
information relating, directly or indirectly, to issuer of one or more financial instruments, 118–20
inside information defined, 206
insider trading, 117
market manipulation provisions, 124–6
market manipulation techniques prohibited, 126
non-public information, 118
overview, 116–17
price-sensitive information, 121–3
prohibited conduct, 117–18
Directive on Takeover Bids
applicability of main provisions, 113–15
application to equity securities, 106
general principles, 114
impact, 115–16
“offeree company” defined, 113
“offeror” defined, 113
overview, 112–13
“takeover bid” defined, 113
Williams Act in relation, 112
Directive on the Public Disclosure of Inside Information
manipulative practices, 126

signs of market manipulation, 125–6
equal treatment rules, 139
Financial Services Action Plan, 105
freedom of services and free movement of capital, 108–10
legal basis of regulation, 106–7
legal framework generally, 30
liability management transactions and treaty freedoms, 110–11
market abuse regulations, 18
Prospectus Directive, 9
regulatory framework overviewed, 35, 104–6
securities market listings, 56
Transparency Directive, 139
treaty basis of securities law harmonization, 111–12
Treaty on the Functioning of the European Union, 107–8
exchequer offers
anti-fraud protection under Section 14(e) of Securities Exchange Act, 193–4
bank compensation, 156
banks, 173–4
definition, 142
exempt or unregistered offers advantages/disadvantages, 144–5
exemptions from registration, 144
registered offers distinguished from, 142
exit consents, 29
information provision by financial advisors, 169–70
interaction of financial advisors and offerees, 167–8
introduction to, 140
legal framework, 141–2
liability management generally, 25–6
as liability management option, 2
misleading omissions, 238–9
by multinational companies across multiple jurisdictions, 142–3
objectives of, 141
INDEX

offshore offers 180
  abuse of exemptions, 190
  Category 1, 187–8
  Category 2, 188
  Category 3, 188–90
  general conditions, 186–7
  introduction to, 183–4
  issuer safe harbor categories, 187
  outside scope of Section 14(e) of Securities Act, 184–5
  Regulation S under Securities Act, 185–90
  safe harbors, 186
  Section 14(e) of Securities Exchange Act, 218–23
  specific conditions, 187
  private placements (Section 4(2) offers), 142, 178
  registered offers
    early commencement (Rule 162 under Securities Act), 146–9
    filing, 146
    introduction to, 145–6
    liability, 149–54
    private/exempt offers distinguished, 142
  Regulation 14(E) under Securities Exchange Act, 191
  Section 3(a)(10) of Securities Act, offers under
    court approval of terms and conditions, 175–6
    fairness hearing, 176
    introduction to, 173–5
    schemes of arrangement in relation to, 176–8
  Section 3(a)(9) of Securities Act, offers under
    advantages, 156
    disadvantages, 156
    exclusivity, 164–6
    identity of issuer, 160–3
    introduction to, 154–5
    methods, 156–8
    no commission or other remuneration, 166–7
    overview, 154
  reasons for offers, 155–6
  Securities Exchange Act in relation to, 173
  statutory conditions, 158–72
  Trust Indenture Act in relation to, 172–3
  types of consideration, 156–8
  Section 4(2) of Securities Act, private placements under
    absence of general solicitation or advertising, 181
    advantages, 178–9
    conditions, 181–3
    disadvantages, 179
    disclosure requirements, 182
    filing of Form D, 182
    introduction to, 178
    investor letter, 182–3
    investor numbers and types, 181–2
    restrictions on resale, 182
    structuring of, 179–80
  Section 14(e) of Securities Exchange Act, 193–4
  transactions constituting, 141
  Trust Indenture Act, 191–3
  types of offers, 142, 143–5
  unregistered offers see exempt or unregistered offers above
  exclusionary offers see offshore offers exclusivity
    Section 3(a)(9) exchange offers, 164–6
  exempt or unregistered debt exchange offers see exchange offers
  exit consents see consent solicitations
  Extension of the Offering Period Rule see Regulation 14E under Securities Exchange Act
  fairness hearing
    exchange offers under Section 3(a)(10) of Securities Act, 176
  false rumors
    market manipulation, 120–1,
    128
<table>
<thead>
<tr>
<th>filing</th>
<th>Hanson test application</th>
</tr>
</thead>
<tbody>
<tr>
<td>avoidance of requirement, 97–8</td>
<td>differentiating between debt and equity tender offers, 62–3</td>
</tr>
<tr>
<td>bankruptcy petition, 212</td>
<td>open market purchases, 60–1</td>
</tr>
<tr>
<td>corporate law, 212</td>
<td>other types of purchases, 62</td>
</tr>
<tr>
<td>as disclosure, 54–5, 203, 209–10</td>
<td>privately negotiated purchases, 61–2</td>
</tr>
<tr>
<td>exempt or unregistered debt exchange offers, 144</td>
<td>factors, 16–17</td>
</tr>
<tr>
<td>form of, 233–4, 269</td>
<td>operating principles, 59–60</td>
</tr>
<tr>
<td>private placements, 180, 182</td>
<td>overview, 58–60</td>
</tr>
<tr>
<td>registered exchange offers, 145, 146, 147</td>
<td>recommendations in light of, 17–18</td>
</tr>
<tr>
<td>requirement generally, 34–5</td>
<td>Wellman test in relation to, 57–9, 60, 61, 197, 199</td>
</tr>
<tr>
<td>Section 3(a)(9) offers, 173</td>
<td>harmonization of securities law</td>
</tr>
<tr>
<td>Trust Indenture Act, 192–3</td>
<td>EU treaties basis, 111–12</td>
</tr>
<tr>
<td>financial advisors</td>
<td>hedging</td>
</tr>
<tr>
<td>information services as to exchange offers, 169–70</td>
<td>causation, 246–7</td>
</tr>
<tr>
<td>interaction with offerees, 167–8</td>
<td>engagement in, 188–90</td>
</tr>
<tr>
<td>Financial Services Action Plan adoption by EU, 105</td>
<td>offshore transactions, 190</td>
</tr>
<tr>
<td>“firm” (offer) definition, 48–9</td>
<td>high-yield debt securities</td>
</tr>
<tr>
<td>fixed spread pricing</td>
<td>Regulation 14E under Securities Exchange Act, 81–2</td>
</tr>
<tr>
<td>Regulation 14E of Securities Exchange Act, 72–3</td>
<td>identity of issuer</td>
</tr>
<tr>
<td>forms see filing</td>
<td>Section 3(a)(9) exchange offers, 160–3</td>
</tr>
<tr>
<td>fraudulent, deceptive, or manipulative acts or practices</td>
<td>identity of tender offeror</td>
</tr>
<tr>
<td>definition, 65</td>
<td>disclosure guidelines, 100</td>
</tr>
<tr>
<td>Section 14(e) of Securities Exchange Act, 242–4</td>
<td>“improper disclosure” defined, 134</td>
</tr>
<tr>
<td>free movement of capital</td>
<td>“in connection with” tender offer see Section 14(e) of Securities Exchange Act, cause of action</td>
</tr>
<tr>
<td>basis of EU liability management regulation, 108–10</td>
<td>indenture terms, amendment see consent solicitations</td>
</tr>
<tr>
<td>freedom of services</td>
<td>information</td>
</tr>
<tr>
<td>basis of EU liability management regulation, 108–10</td>
<td>consent solicitations see consent solicitations</td>
</tr>
<tr>
<td>“fundamental change” defined, 284</td>
<td>disclosure see disclosure requirements</td>
</tr>
<tr>
<td>fundamental economic terms amendment of indenture terms, 256–7</td>
<td>dissemination guidelines, 101–3</td>
</tr>
<tr>
<td>Goldman Sachs Extension of the Offering Period Rule, 77–9</td>
<td>equity tender offer rules as to, 34–5</td>
</tr>
<tr>
<td>exchange offers see exchange offers filing see filing</td>
<td>exchange offers see exchange offers</td>
</tr>
<tr>
<td>information services as to exchange offers, 169–70</td>
<td></td>
</tr>
</tbody>
</table>
Index

market interest  
“SUSMI” defined, 187  
market manipulation  
contract-based manipulations, 131  
definition, 124, 126–8  
EU regulation see European Union  
“manipulate” defined, 242–3  
manipulating devices, 138  
manipulating transactions, 135–8  
market power manipulations, 131  
purchases or sales of securities with manipulative intent, 129–30, 131  
signs of, 125–6  
types of, 124  
market power manipulations overview, 131  
market risk  
exposure, 76, 136–7  
manipulation of transactions, 135–6, 138  
reduction, 136–7  
market value  
cash payment exceeding, 290, 295  
greater level of, 165  
real value conferred, 295  
material non-public information see non-public information  
material terms, unanimous consents  
Section 316(b) of Trust Indenture Act, 257–63  
materiality  
causation distinguished, 228–9  
cause of action, 225–9  
finding of, 19–20, 203–4  
“material” defined, 225–6  
“material fact” defined, 19–20, 203–4  
misleading material omission, concept of, 225  
misleading nature of statement distinguished, 228–9  
reliance distinguished, 228–9  
scienter distinguished, 228–9  
Merrill Lynch, Pierce, Fenner & Smith Incorporated  
Extension of the Offering Period Rule, 74–7  

INDEX  
mini-tender offers  
disclosure guidelines, 98–101  
dissemination guidelines, 101–3  
overview, 97–8  
misleading nature of statement  
materiality distinguished, 228–9  
misleading omissions of material fact see Section 14(e) of Securities Exchange Act, material misrepresentations and omissions  
misrepresentations overview, 128  
“misuse of information” defined, 134–5  
“movements of capital” defined, 110–11  
multinational corporations see corporations  
mutual recognition of national laws  
EU treaty freedoms, 109  
national laws of EU member states  
mutual recognition, 109  
no-action letters  
18-day and 20-day fixed spread pricing, 81  
“20 Business Days” Rule, 68–9  
consent solicitations, 271–2, 274, 277–84  
fixed-spread pricing, 72–3, 75, 78  
fixed-spread pricing case law, 73–4  
pricing mechanisms, 82–4  
regulation generally, 32–3  
Rule 14E under Securities Exchange Act, 65  
Section 3(a)(9) exchange offers, 160–1, 163, 168–9  
Section 3(a)(10) exchange offers, 174–5, 176–7  
waterfall structures, 89–90  
non-public information  
concealment of, 240–1  
in context of tender offers, 92–5  
definition, 118, 204, 206  
disclosure requirements, 20–1, 200–3, 204–5, 207–8, 209–10, 241
possession of, 20, 200, 248–9, 251
prohibited conduct, 20, 94, 200–2
regulatory framework, 32–3, 94
Notice of Extensions Rule
Regulation 14E of Securities
Exchange Act, 85–6
offer price
disclosure guidelines, 98–9
offer terms
Wellman test, 49
“offeree company”
defined, 113
offerees
interaction with financial advisors, 167–8
“offeror”
defined, 113
offeror’s identity
disclosure guidelines, 100
offers to purchase
Wellman test see Wellman test
offshore offers see exchange offers
omissions see Section 14(e) of
Securities Exchange Act,
material misrepresentations
and omissions
open market purchases
application of Hanson test and
Wellman test, 60–1
optional redemption
as liability management option, 2
options
appeal of, 8
availability, 11–12
compliance, 13
eyearly commencement, 148
employee stock ownership plans,
155–6
exercise of, 40–1, 261–2, 275–6
exit consents, 293
factors in choice of, 3
insider trading, 92
limitation on use, 11
range of, 2
repricing, 56–7
reservation of, 40–1
time extension, 15
types distinguished, 12–13
volatility movements, 137–8
partial tender offers
prohibited transactions, 96
plans or proposals
disclosure guidelines, 100
pre-commencement communications
prohibited conduct, 97
“premium”
defined, 48
price changes
disclosure guidelines, 99
price-sensitive information
definition, 121–2, 206–7
effect when publicly known,
121–3
see also inside information
pricing mechanisms
Regulation 14E of Securities
Exchange Act, 70–1
principal amount, Wellman test see
Wellman test
private placements
Section 4(2) of Securities Act, 178
privately negotiated purchases
application of Hanson test and
Wellman test, 61–2
pro rata acceptance
disclosure guidelines, 99
prohibited conduct
pre-commencement
communications, 97
prohibited transactions
partial tender offers, 96
Prompt Payment Rule
“prompt” defined, 84
Regulation 14E of Securities
Exchange Act, 84–5
prospectus
delivery, 142, 144, 149, 154–6,
173–4, 272–3
Directive, 9
EU regulation, 104–6
liability, 149–51
preliminary prospectus, 147–8
prohibited conduct, 170–1
review, 145
prospectus (cont.)
revision, 148
supplement, 148
“proxy”
defined, 266
“public”
definition for trading purposes, 205
public announcements
artificial transactions, 128–9
consent solicitations, 270–1
disclosure via, 21, 208–9
Dutch auctions, 71–2
extensions of tender offers, 85–6
finding of, 16
Hanson test as to, 17–18
“in connection with” tender offer
debt repurchases, 18–20
period after announcement of
tender offer, 250
pre-announcement period, 97, 153–4, 248–9
misrepresentations in, 217, 230–2
timing, 48–9, 71–2, 89–90, 197–8, 234–5
Wellman test as to, 16, 17–18, 42–3, 54–6, 196–7
public information see information
purchase offers
Wellman test see Wellman test
purchases of debt securities see debt
securities
purchases or sales of securities with
manipulative intent
overview, 129–30, 131
redemption
exercise of right, 8
Regulation 10B-5 of Securities
Exchange Act
debt repurchases, 18–20
Section 14(e) in relation, 223–4
Regulation 14E of Securities Exchange
Act
“10 plus 10” tender offers, 87–8
“20 Business Days” Rule (Regulation
14E-1(a)), 66–9
debt tender offers regulation
generally, 64–5
disclosure requirements
(“mini-tender offer
interpretative release”)
disclosure guidelines, 98–101
dissemination guidelines, 101–3
overview, 97–8
exchange offers, 191
Extension of the Offering Period
Rule (Rule 14e-1(b))
18-day and 20-day fixed-spread
pricing, 80–1
Dutch auctions, 71–2
fixed-spread pricing, 72–3
high-yield debt securities, 81–2
other types of transactions, 82–4
overview, 69–70
pricing mechanisms, 70–1
Notice of Extensions Rule (Rule
14e-1(d)), 85–6
position of subject company with
respect to tender offer (Rule
14e-2), 91–2
prohibited conduct in connection
with pre-commencement
communications (Rule 14e-8), 97
prohibited transactions in
connection with partial tender
offers (Rule 14e-4), 96
Prompt Payment Rule (Rule
14e-1(c)), 84–5
transactions in securities on basis of
material, non-public
information in context of
tender offers (Rule 14e-3), 92–5
unlawful tender offer practices
(Rule 14e-1), 66
“waterfall” structures, 88–91
withdrawal rights, 86–7
Regulation FD under Securities
Exchange Act
debt repurchases, 209–10
Regulation M under Securities
Exchange Act
debt repurchases, 210
Regulation S of Securities Act
offshore offers, 185–90

Releases see Securities and Exchange Commission (SEC)
reliance
cause of action, 245–6
materiality distinguished, 228–9
repurchases of debt securities see debt repurchases
required mental state see scienter
release restrictions
Section 4(2) exchange offers, 182
rumors
market manipulation, 120–1, 128

safe harbors see exchange offers, offshore offers
Salomon Brothers No-Action Letter
Extension of the Offering Period Rule, 73
schemes of arrangement
Section 3(a)(10) exchange offers in relation, 176–8
scienter (required mental state)
cause of action, 244
definition, 244–5
materiality distinguished, 228–9
secondary markets
debt securities transactions, 6–7
secondary transactions
concept of, 7
Section 14(e) of Securities Exchange Act
anti-fraud protection as to exchange offers, 193–4
applicability generally, 215–16
cause of action
causation, 246–7
elements generally, 244
“in connection with” tender offer: “in connection with” defined, 248; introduction to, 248; period after announcement of tender offer, 250; period after termination of tender offer, 250; pre-announcement period, 97, 153–4, 248–9; transactions in securities on basis of material non-public information in context of tender offers, 251
injury, 247
material misrepresentations and omissions, see material misrepresentations and omissions below
materiality, 225–9
reliance, 245–6
required mental state (scienter), 244
standing to sue, 247–8
fraudulent, deceptive, or manipulative acts or practices, 242–4
general application, 216–18
introduction to, 214–15
material misrepresentations and omissions
by brokers or dealers, 241
introduction to, 224–5
materiality, 225–9
misleading omissions by issuers of tender securities, 239–41
misleading omissions by tender offerors, 232–8
misleading omissions in exchange offers, 238–9
misrepresentations in tender offer documents and other public announcements, 230–2
omission defined, 225
potential violators, 229
purpose and rationale of tender offer, 237–8
tax consequences of tender offer, 236–7
terms and conditions of tender offer, 235–6
offshore offers, 218–23
Regulation 10B-5 of Securities Exchange Act in relation, 223–4
Securities Act, exchange offers see exchange offers
Securities and Exchange Commission (SEC)
compliance see compliance enforcement, 15, 73–4, 81, 151–2, 192, 247–8, 281–2
filing see filing
"New Security" Doctrine, 277–84
no-action letters see no-action letters releases high-yield debt securities, 81
mini-tender offer interpretative release, 97–8
offshore offers, 183–5, 189–90, 220–1
regulation generally, 29–30
Regulation S, 185, 190
tender offers defined, 45–6
Securities Exchange Act
anti-fraud protection (Section 14(e)) see Section 14(e) of Securities Exchange Act
debt tender offers (Regulation 14E) see Regulation 14E of Securities Exchange Act
exchange offers see exchange offers
exit consents (Regulation 14A) see consent solicitations provisions overviewed, 31–2
regulatory framework overviewed, 31–3
see also Williams Act
securities law harmonization
EU treaties basis, 111–12
selling pressure
Wellman test, 51–4
shareholder actions
derivatives, 212
solicitation agents
banks as, 28
solicitation of consents see consent solicitations
standing to sue
cause of action, 247–8
substantial US market interest (SUSMI)
definition, 187
takeovers see corporate takeovers
target recommendation
disclosure guidelines, 99–100
taxation
debt repurchases, 22, 212–13
misleading omissions as to tax consequences of tender offer, 236–7
tender offeror’s identity
disclosure guidelines, 100
tender offers
banks and, 102–3, 220–1, 223–4
debt repurchases see debt repurchases
definition within US rules avoidance as to repurchases, 15–18
conventional tender offer, 40–1
debt and equity offers distinguished, 62–3
Hanson test see Hanson test
introduction to, 38–40
issued securities, 23
Wellman test see Wellman test
differing rules, 33–5
exit consents, 29
negotiations found to be not, 59–60
rationale for regulation, 29–31
unlawful practices generally, 66
tender securities
misleading omissions as to, 239–41
terms and conditions
amendment see consent solicitations misleading omissions, 235–6
Wellman test, 49
time
offer periods, 50–1
option extension, 15
public announcements, 48–9, 71–2, 89–90, 197–8, 234–5
"total mix" of available information concept of, 19–20, 203–4
Transparency Directive implementation, 139
Treaty on the Functioning of the European Union
basis of liability management regulation, 107–8
## Index

<table>
<thead>
<tr>
<th>Page</th>
<th>Term</th>
</tr>
</thead>
<tbody>
<tr>
<td>309</td>
<td>trust deeds</td>
</tr>
<tr>
<td>309</td>
<td>debt repurchases, 211</td>
</tr>
<tr>
<td>309</td>
<td>Trust Indenture Act</td>
</tr>
<tr>
<td>309</td>
<td>amendment of indenture terms, consent solicitations (Section 316(b)), 257–63</td>
</tr>
<tr>
<td>309</td>
<td>exchange offers, 172–3, 191–3</td>
</tr>
<tr>
<td>309</td>
<td>exit consents, 291, 292–3</td>
</tr>
<tr>
<td>309</td>
<td>“New Security” Doctrine, 272–5, 276–7</td>
</tr>
<tr>
<td>309</td>
<td>unanimous consents for material terms</td>
</tr>
<tr>
<td>309</td>
<td>Section 316(b) of Trust Indenture Act, 257–63</td>
</tr>
<tr>
<td>309</td>
<td>underwriting banks see banks</td>
</tr>
<tr>
<td>309</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>309</td>
<td>equal treatment rules, 139</td>
</tr>
<tr>
<td>309</td>
<td>exit consents, 293–5</td>
</tr>
<tr>
<td>309</td>
<td>market abuse regulation description of market abuse, 132–9</td>
</tr>
<tr>
<td>309</td>
<td>introduction to, 131–2</td>
</tr>
<tr>
<td>309</td>
<td>pricing mechanisms, case law, 84</td>
</tr>
<tr>
<td>309</td>
<td>regulatory framework overviewed, 30, 35, 104, 113, 115, 127–8</td>
</tr>
<tr>
<td>309</td>
<td>schemes of arrangement, 176–8 tax issues as to repurchases, 212–13</td>
</tr>
<tr>
<td>309</td>
<td>trust deed, 211</td>
</tr>
<tr>
<td>309</td>
<td>unlawful tender offer practices Regulation 14E of Securities Exchange Act, 66</td>
</tr>
<tr>
<td>309</td>
<td>unregistered debt exchange offers see exchange offers, exempt or unregistered offers</td>
</tr>
<tr>
<td>309</td>
<td>untrue statements see Section 14(e) of Securities Exchange Act, material misrepresentations and omissions</td>
</tr>
<tr>
<td>309</td>
<td>voting rights definition, 5</td>
</tr>
<tr>
<td>309</td>
<td>waivers definition, 27</td>
</tr>
<tr>
<td>309</td>
<td>Wellman test active and widespread solicitation of public security holders, 43–6</td>
</tr>
<tr>
<td>309</td>
<td>application differentiating between debt and equity tender offers, 62–3 open market purchases, 60–1 other types of purchases, 62 privately negotiated purchases, 61–2</td>
</tr>
<tr>
<td>309</td>
<td>factors evaluated, 16, 196–7 “firm” (offer) defined, 48–9</td>
</tr>
<tr>
<td>309</td>
<td>further considerations, 56–7 Hanson test in relation, 57–9, 60, 61, 197, 199</td>
</tr>
<tr>
<td>309</td>
<td>offer only open for limited period, 50–1</td>
</tr>
<tr>
<td>309</td>
<td>offer subject to minimum condition, and often subject to fixed principal amount to be purchased, 49–50</td>
</tr>
<tr>
<td>309</td>
<td>offer to purchase made at premium to prevailing market price, 48–9</td>
</tr>
<tr>
<td>309</td>
<td>offerees subject to selling pressure, 51–4 overview, 41–3</td>
</tr>
<tr>
<td>309</td>
<td>public announcement of purchasing program precedes or accompanies rapid accumulations of large amounts of the company’s securities, 54–6</td>
</tr>
<tr>
<td>309</td>
<td>recommendations in light of, 17–18 solicitation of substantial percentage of outstanding principal amount, 46–8</td>
</tr>
<tr>
<td>309</td>
<td>terms of offer are firm rather than negotiable, 49</td>
</tr>
<tr>
<td>309</td>
<td>Section 14(e) see Section 14(e) of Securities Exchange Act “tender offer” defined see tender offers</td>
</tr>
</tbody>
</table>
withdrawal rights
  disclosure guidelines, 99
  Regulation 14E of Securities
  Exchange Act, 86–7

words and phrases
  any court, 175–6
  dissemination, 138
  distortion, 138–9
  economic rights, 5
  equity tender offers, 23
  firm (offer), 48–9
  fraudulent, deceptive, or
  manipulative acts or practices,
  65
  fundamental change, 284
  improper disclosure, 134
  inside information, 118, 206
  interstate commerce, 183
  market abuse, 132–9
  market manipulation, 124,
  126–8

material, 225–6
material fact, 19–20, 203–4
misuse of information, 134–5
movements of capital, 110–11
non-public information, 118, 204,
  206
offeree company, 113
offeror, 113
premium, 48
price-sensitive information, 121–2,
  206–7
proxy, 266
scienter (required mental state),
  244–5
solicitation, 43, 267
substantial US market interest
  (SUSMI), 187
takeover bid, 113
tender offers see tender offers
voting rights, 5
waivers, 27